ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company's latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity.
McCarthy emphasised that P140 remains the company’s primary focus, with ongoing licensing discussions described as highly active. He stated, “We are delivering a deal this year. We're confident of doing that,” highlighting continued engagement with multiple potential partners, including new parties that have approached the company since late 2025.
Alongside this, ImmuPharma has advanced Kapiglucagon into an accelerated development program following interest and funding support from existing shareholders. The asset, targeting Type 1 diabetes (T1D), is designed to address limitations in current glucose delivery systems. McCarthy explained that Kapiglucagon offers improved solubility and stability, making it suitable for next-generation dual hormone pumps.
The company has secured funding led by Lanstead Capital Investors to support a two-year development plan, with the goal of progressing Kapiglucagon toward potential licensing discussions. McCarthy noted that early engagement with industry players has already generated strong interest.
Despite the expansion of its pipeline, McCarthy reiterated that the company’s strategy remains centred on P140, stating that “our total focus has not been diverted one iota in pushing forward those license discussions.”
For more insights into ImmuPharma’s strategy and upcoming milestones, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates.
#ImmuPharma #TimMcCarthy #P140 #Kapiglucagon #BiotechNews #PharmaNews #DrugDevelopment #DiabetesResearch #Type1Diabetes #BiotechInvesting #HealthcareInnovation #ClinicalDevelopment #LicensingDeals #SmallCapStocks #AIMStocks
